Halia Therapeutics, Inc.

Exercise Fights Chronic Inflammation and Boosts Long-Term Health A recent The New York Times article highlights a growing body of research—exercise isn’t just good for fitness; it’s one of the best ways to fight chronic inflammation. 🔥 Key Takeaways from the Article: ✔️ Inflammation is a double-edged sword—while it helps heal injuries and fight infections, chronic inflammation is linked to heart disease, diabetes, dementia, and more. ✔️ Sedentary lifestyles fuel inflammation. Studies show that inactive people have higher levels of inflammatory markers, but consistent exercise reduces them over time. ✔️ How does exercise help? Moderate workouts: Reduce the release of pro-inflammatory chemicals Increase anti-inflammatory compounds Improve sleep and lower stress—both of which contribute to inflammation ✔️ Fat cells are part of the problem. Sedentary people tend to have fat cells that release inflammatory substances. Exercise helps shrink these fat cells and reprograms them to be less inflammatory. 🏃♂️ How to Maximize Exercise’s Anti-Inflammatory Effects: 🔹 Move regularly—even a 20-minute moderate-intensity workout can trigger an anti-inflammatory response. 🔹 Prioritize strength training—resistance exercises reduce inflammation-causing fat cells and help maintain mobility. 🔹 Choose workouts that lower stress—yoga and mindfulness-based exercise can directly lower inflammatory markers. 🔹 Don’t overtrain—high-intensity exercise can temporarily spike inflammation, so recovery is key. HT-6184 targets the NLRP3 inflammatory pathway in adipose (fat) tissue, shifting the balance from pro-inflammatory M1 to anti-inflammatory M2 macrophages. This shift reduces metaflammation, potentially improving metabolic health and making obesity treatments more effective. Exercise and science together can reshape how we treat obesity. While movement is a powerful tool, HT-6184 is designed to enhance these natural mechanisms, helping people sustain long-term health improvements. We can fight inflammation with science, movement, and innovation. What are your thoughts on the role of exercise in reducing inflammation? https://lnkd.in/dGQpzCX7 #Inflammation #ExerciseScience #Longevity #Biotech #HealthInnovation #HaliaTx

Exercise Fights Chronic Inflammation and Boosts Long-Term Health A recent The New York Times article highlights a growing body of research—exercise isn’t just good for fitness; it’s one of the best ways to fight chronic inflammation. 🔥 Key Takeaways from the Article: ✔️ Inflammation is a double-edged sword—while it helps heal injuries and fight infections, chronic inflammation is linked to heart disease, diabetes, dementia, and more. ✔️ Sedentary lifestyles fuel inflammation. Studies show that inactive people have higher levels of inflammatory markers, but consistent exercise reduces them over time. ✔️ How does exercise help? Moderate workouts: Reduce the release of pro-inflammatory chemicals Increase anti-inflammatory compounds Improve sleep and lower stress—both of which contribute to inflammation ✔️ Fat cells are part of the problem. Sedentary people tend to have fat cells that release inflammatory substances. Exercise helps shrink these fat cells and reprograms them to be less inflammatory. 🏃♂️ How to Maximize Exercise’s Anti-Inflammatory Effects: 🔹 Move regularly—even a 20-minute moderate-intensity workout can trigger an anti-inflammatory response. 🔹 Prioritize strength training—resistance exercises reduce inflammation-causing fat cells and help maintain mobility. 🔹 Choose workouts that lower stress—yoga and mindfulness-based exercise can directly lower inflammatory markers. 🔹 Don’t overtrain—high-intensity exercise can temporarily spike inflammation, so recovery is key. HT-6184 targets the NLRP3 inflammatory pathway in adipose (fat) tissue, shifting the balance from pro-inflammatory M1 to anti-inflammatory M2 macrophages. This shift reduces metaflammation, potentially improving metabolic health and making obesity treatments more effective. Exercise and science together can reshape how we treat obesity. While movement is a powerful tool, HT-6184 is designed to enhance these natural mechanisms, helping people sustain long-term health improvements. We can fight inflammation with science, movement, and innovation. What are your thoughts on the role of exercise in reducing inflammation? https://lnkd.in/dGQpzCX7 #Inflammation #ExerciseScience #Longevity #Biotech #HealthInnovation #HaliaTx

Exploring a New Approach to Reducing Alzheimer’s Risk in APOE4 Carriers At Halia Therapeutics, we’re developing HT-4253, a novel investigational drug designed to reduce Alzheimer’s risk in APOE4 carriers. Research shows that individuals with two copies of APOE4 have up to a 60% chance of developing dementia by age 65—highlighting the urgent need for early intervention strategies. Our approach is based on a genetic breakthrough: a rare mutation in RAB10 that provides natural protection against APOE4-related Alzheimer’s. Instead of directly targeting RAB10 (which is challenging), we’ve developed HT-4253, which inhibits LRRK2, a key regulator of RAB10, to mimic this protective effect. 📢 Join us at the AAIC Advancements: APOE & Lipid Biology Conference on March 17-18 in Miami, where we’ll present our latest findings on HT-4253’s potential to reshape Alzheimer’s prevention. 🎥 Watch this video of our Director of Neuroscience Research, Russ Teichert, MBA, PhD, as he walks through our poster presentation. #AlzheimersResearch #Neuroscience #HT4253 #Biopharma #Innovation #APOE4 #Neurodegeneration

At the BioLabs France Investor Day on March 11 in Paris, we had the pleasure and privilege to award Golden Tickets to no less than four strong start-ups working on novel therapeutic concepts for delivering innovative medicines to combat cardiometabolic disease.   At Novo Nordisk, we are dedicated to improving treatment outcomes and lives of people living with cardiometabolic disease, through discovery and development of cutting-edge therapeutics. To deliver on this commitment, we support translation of basic science into drug discovery in our Science2Medicine program (visit www.novonordisk.com to learn more). We are proud of our partnership with BioLabs France and BioLabs Heidelberg to provide start-ups with access to state-of the-art lab facilities and inclusion in a buzzing community of entrepreneurs and investors 🚀   Huge congratulations to Halia Therapeutics, Inc., Halo Therapeutics, NewCo from Melbourne (Profs. Dodd and Hossain) and Scenic Biotech for sharing their awesome science with us – and we truly look forward to working with you and supporting your journeys toward success!   A heartfelt THANK YOU to Johannes Fruehauf, Johanna Michielin and the great teams at BioLabs France (especially Christophe Tallec and Chaimaa Asri) and BioLabs Heidelberg (especially Ann-Kristin Mueller and Stefanie Schimmel) for their amazing efforts in making all of this possible and for creating a wonderful, productive and festive partnering event in Paris 🙏

Halia Therapeutics Wins Novo Nordisk Golden Ticket to Advance Obesity & Inflammation Research We’re excited to announce that Halia Therapeutics has been awarded the prestigious Novo Nordisk Golden Ticket. This provides us access to Biolabs' state-of-the-art facilities and expert mentorship from Novo Nordisk's scientific and business leaders. This recognition will accelerate the development of HT-6184, our first-in-class NEK7/NLRP3 inflammasome inhibitor. Why This Matters •      Validates our innovative approach to addressing chronic inflammation and obesity-related diseases •      Enhances our research capabilities with premium laboratory space and resources •      Strengthens our global footprint through strategic partnerships in the European biotech ecosystem HT-6184 targets metaflammation—the low-grade chronic inflammation associated with obesity and metabolic dysfunction. Our preclinical studies demonstrate that HT-6184 significantly enhances the effectiveness of GLP-1 receptor agonists, promoting weight loss while preserving lean muscle mass and reducing inflammatory markers. With our upcoming Phase 2 clinical study evaluating HT-6184 in combination with semaglutide, this award positions Halia Therapeutics to make meaningful advances in obesity and metabolic disease treatment. We sincerely thank Novo Nordisk and BioLabs for this transformative opportunity. We're excited to leverage these new resources and collaborations to drive innovations that could reshape metabolic health treatments. Read the full press release here: https://lnkd.in/gyeZFXtj Learn more about our work at www.haliatx.com #BiotechInnovation #ObesityResearch #InflammationScience #NovoNordiskPartnership #MetabolicHealth #DrugDiscovery #GLP1Therapies #HT6184 #HaliaTx

Halia Therapeutics CEO to Deliver Keynote on NEK7-NLRP3 Inhibition at Drug Discovery Innovation Programme (DDIP) Halia Therapeutics is pleased to announce that Dr. David Bearss Ph.D. our CEO, will be the keynote speaker at the Drug Discovery Innovation Programme in San Diego, CA. Dr. Bearss will present our innovative approach to targeting inflammation through NEK7-NLRP3 inhibition, which disrupts inflammasome activation at its core. This approach prevents assembly and promotes disassembly of the NLRP3 inflammasome, offering the potential for treating a range of inflammatory-driven diseases, including metabolic disorders, neuroinflammation, and autoimmune conditions. Attending the event? Join us to learn how inflammasome modulation is advancing drug discovery and how HT-6184 and Halia's pipeline are developing effective inflammation-targeted therapies. 📍 Hilton San Diego Bayfront 📅 March 3, 2025 #HaliaTx #DrugDiscovery #Inflammation #NEK7 #NLRP3 #Biotech #DDIP2025

David Bearss has been named Visionary of the Year at Best of BioHive 2025 This award recognizes a Utah-based company making groundbreaking strides in therapeutics with strong market traction, funding, and development—and we couldn’t be prouder to see Dr. Bearss and Halia honored for our mission to transform patient care through next-generation inflammation-targeted therapies. At Halia, we don’t compete with other biopharmaceutical companies—we compete against the diseases we are researching to find treatments for. Every step we take is a step toward better solutions for patients, and this recognition is a testament to our unwavering commitment to that mission. This special night was made even more meaningful by the attendance of Halia’s three co-founders—David Bearss Ph.D., John Kauwe, and Jared Bearss. These three have been instrumental in shaping our vision, driving innovation, and advancing our scientific breakthroughs. Their leadership and dedication have positioned Halia as a rising force in biopharma, and we’re just getting started. A huge thank you to BioHive Utah for this honor and to all our partners and supporters who believe in our vision! The future of biotech is here, and together, we are pushing the boundaries of medicine. #BestOfBioHive #VisionaryOfTheYear #HaliaTx #Biotech #Innovation #LifeSciences #Therapeutics

🎙️ Introducing the Good Medicine Podcast with David Bearss! 🎙️ We’re excited to announce that David Bearss Ph.D. is launching the Good Medicine Podcast – a deep dive into the cutting edge of biotech, drug discovery, and the future of medicine. As a biotech entrepreneur, scientist, and leader in drug development, David has spent his career pushing the boundaries of medicine. Now, he’s bringing his insights, experiences, and expert guests straight to you! 💡 What to expect: ✅ In-depth conversations with industry leaders ✅ Breakthroughs in biotech and drug development ✅ Lessons from an entrepreneur in the life sciences Stay tuned for the first episode dropping soon! 🔬🎧 Follow the Good Medicine Podcast and be part of the conversation. #GoodMedicinePodcast #Biotech #HealthcareInnovation #DrugDiscovery #Entrepreneurship

Halia Therapeutics is proud to sponsor the BioHive Utah event, BioHive Live, Utah's premier life sciences and healthcare innovation event! 🎉 Join us at Hale Centre Theatre on February 20, 2025, where our CEO, David Bearss Ph.D., will participate in the "Why We Do It" panel discussion from 1:05 pm to 1:35 pm. He will share insights about the driving forces behind biotech innovation and Halia's progress in developing inflammation-targeted therapies. This event offers an exceptional opportunity to connect, collaborate, and explore the frontiers of biotech innovation! Let’s drive innovation together! #BioHiveLive #HaliaTx #BioHive #Innovation #Healthcare #LifeSciences

It was an incredible moment for our CEO, David Bearss, Ph. D., and our CFO, Jeff Burton. Together with other biotech leaders, they rang the Nasdaq bell, marking the start of #JPM2025. We are honored to represent Utah's life science community and showcase the innovative and groundbreaking work happening in our state. Can't wait to see what 2025 brings! #BioUtah #UtahLifeSciences #NASDAQ #HaliaTx